Christian Winther Eskelund

International Medical Manager
Novo Nordisk A/S

Presentation(s):

• OC 40.1 - FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy

  Monday, July 11, 2022
  2:45 PM – 3:00 PM

• OC 50.5 - Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors

  Tuesday, July 12, 2022
  11:45 AM – 12:00 PM

• PB1163 - Real-World Unmet Needs of Patients with Haemophilia A/B with or without Inhibitors: Historical Haemophilia Characteristics from Patients Entering a Non-Interventional Study

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• OC 70.3 - Unmet Medical Needs in Patient-Reported Outcomes and Sports Activity in People with Haemophilia A/B with or without Inhibitors: Historical Data from Patients Entering a Non-Interventional Study

  Wednesday, July 13, 2022
  10:45 AM – 11:00 AM